Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):16-23. doi: 10.1097/ACI.0000000000000707.
Allergen-specific immunotherapy has established as an indispensable disease-modifying treatment in allergy practice but its safety and efficacy might be furtherly improved by combining it with other drugs or therapeutic intervention that co-modulate immune type 2 immune networks.
In the past two decades, clinical research focused on AIT and omalizumab co-treatment to improve both safety and long-term efficacy of allergic disease treatment. Recently, combination of AIT with other biologicals targeting different mediators of type 2 inflammation has been set up with interesting preliminary results. Moreover, AIT current contraindication might be overcome by contemporarily controlling underlying type 2 inflammation in severe atopic patients.
AIT--biological combination treatment can realize a complex multitargeted treatment strategy allowing for consistently improving disease control and sparing steroid administration.
变应原特异性免疫疗法已被确立为过敏实践中不可或缺的疾病修正治疗方法，但通过与其他药物或共同调节免疫 2 型免疫网络的治疗干预相结合，其安全性和疗效可能进一步提高。
在过去的二十年中，临床研究集中在 AIT 和奥马珠单抗联合治疗上，以提高过敏疾病治疗的安全性和长期疗效。最近，AIT 与针对 2 型炎症不同介质的其他生物制剂联合应用取得了有趣的初步结果。此外，通过同时控制重症特应性皮炎患者的潜在 2 型炎症，可以克服 AIT 当前的禁忌症。
AIT-生物联合治疗可以实现复杂的多靶点治疗策略，从而持续改善疾病控制并减少类固醇的使用。
